In well-selected patients in experienced centers, cytoreductive surgery (CRS) and
hyperthermic intraperitoneal chemotherapy (HIPEC) can be performed for colorectal
peritoneal metastasis with acceptable morbidity and are associated with prolonged
survival.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Peritoneal carcinomatosis from colorectal cancer.Br J Surg. 2002; 89: 1545-1550
- Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.Br J Surg. 2012; 99: 699-705
- Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.Ann Surg. 2006; 243: 212-222
- Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study.Eur J Surg Oncol. 2013; 39: 707-714
- Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.J Clin Oncol. 2009; 27: 681-685
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care.Cancer Treat Rev. 2016; 48: 42-49
- Colorectal peritoneal metastases: pathogenesis, diagnosis and treatment options - an evidence-based update.ANZ J Surg. 2020; 90 (Epub 2020 Mar 4. PMID: 32129577): 1592-1597https://doi.org/10.1111/ans.15796
- Colorectal peritoneal metastases: Optimal management review.World J Gastroenterol. 2019; 25: 3484-3502
- TNM classification of malignant tumours.8th Edition ed. Wiley, Springer-Verlag Berlin Heidelberg2017
- Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.Cancer. 2000; 88: 358-363
- The prognostic relevance of histological subtype in patients with peritoneal metastases from colorectal cancer: a nationwide population-based study.Clin Colorectal Cancer. 2015; 14: e13-e19
- Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.Ann Surg. 1995; 221: 124-132
- Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C.Cancer Treat Res. 1996; 81: 51-61
- The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).Eur J Surg Oncol. 2018; 44: 1942-1948
- American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.J Surg Oncol. 2014; 110: 777-778
- Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.J Clin Oncol. 2004; 22: 3284-3292
- Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.World J Surg Oncol. 2019; 17: 83
- Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.J Am Coll Surg. 2006; 203: 878-886
- Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.J Clin Oncol. 2010; 28: 63-68
- Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer.Ann Surg Oncol. 2016; 23: 114-119
- Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis.J Surg Oncol. 2009; 99: 9-15
- Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.Ann Surg Oncol. 2010; 17: 1330-1336
- Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients.Ann Surg Oncol. 2008; 15: 3422-3432
- Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases.Eur J Surg Oncol. 2020; 46: 737-739
- HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma.BMC Cancer. 2018; 18: 183
- Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States.Ann Surg Oncol. 2014; 21: 1501-1505
- Summary of current therapeutic options for peritoneal metastases from colorectal cancer.J Surg Oncol. 2013; 107: 566-573
- Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.Eur J Cancer. 2016; 53: 155-162
- 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.Ann Surg Oncol. 2008; 15: 2426-2432
- Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program.JAMA Surg. 2014; 149: 170-175
- Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly.Surg Oncol. 2013; 22: 184-189
- The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy.Nutr J. 2013; 12: 118
- Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer.World J Surg. 2006; 30: 2025-2032
- Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures.JAMA Netw Open. 2019; 2: e186847
- Major influence of postoperative complications on costs of cytoreductive surgery and HIPEC in patients with colorectal peritoneal metastases.Medicine (Baltimore). 2018; 97: e0042
- Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Early Results from a Prospective Cohort Study of 115 Patients.Ann Surg Oncol. 2020; 27 (Epub 2020 Apr 13. PMID: 32285283.): 3986-3994https://doi.org/10.1245/s10434-020-08443-4
- Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk?.Ann Surg Oncol. 2013; 20: 226-232
- Cost-effectiveness analysis of cytoreductive surgery and HIPEC compared with systemic chemotherapy in isolated peritoneal carcinomatosis from metastatic colorectal cancer.Ann Surg Oncol. 2019; 26: 1110-1117
- The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.J Surg Oncol. 2014; 110: 779-785
- Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.Eur J Surg Oncol. 2020; 46 (Epub 2020 Apr 18. PMID: 32340819): 1902-1907https://doi.org/10.1016/j.ejso.2020.04.018
- The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.J Surg Oncol. 2014; 109: 527-532
- Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.Eur J Surg Oncol. 2018; 44: 220-227
- Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.J Surg Oncol. 2020 Jun; 121 (Epub 2020 Apr 1. PMID: 32239529): 1298-1305https://doi.org/10.1002/jso.25920
- Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.Eur J Surg Oncol. 2017; 43: 144-149
- The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review.Ann Surg Oncol. 2017; 24: 705-720
- Quantitative prognostic indices in peritoneal carcinomatosis.Eur J Surg Oncol. 2006; 32: 597-601
- Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Ann Surg Oncol. 2016; 23: 2841-2848
- Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.Ann Surg Oncol. 2014; 21: 3023-3028
- Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review.J Clin Med. 2020; 9
- Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).BMC Cancer. 2019; 19: 390
- Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without Mitomycin C-based HIPEC: a comparative study using the Peritoneal Surface Disease Severity Score (PSDSS).Ann Surg Oncol. 2020; 27: 98-106
- A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.J Clin Oncol. 2018; 36
- Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.BMC Cancer. 2015; 15: 428
- Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.Lancet Oncol. 2020; 21: 1147-1154
- Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis.Ann Surg. 2011; 254: 289-293
- Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.Cancer. 2010; 116: 3756-3762
- Peritoneal metastases of lower gastrointestinal tract origin:a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy.J Cancer Res Clin Oncol. 2013; 139: 1899-1908
Article info
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
